Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Income: 2020-2025

Historic Net Income for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$24.3 million.

  • Janux Therapeutics' Net Income rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
  • Janux Therapeutics' Net Income amounted to -$24.3 million in Q3 2025, which was up 28.19% from -$33.9 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Net Income ranged from a high of -$2.3 million in Q1 2021 and a low of -$33.9 million during Q2 2025.
  • Its 3-year average for Net Income is -$19.0 million, with a median of -$17.5 million in 2023.
  • Per our database at Business Quant, Janux Therapeutics' Net Income plummeted by 757.17% in 2021 and then spiked by 65.96% in 2024.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Net Income stood at -$13.4 million in 2021, then decreased by 19.75% to -$16.1 million in 2022, then increased by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then rose by 13.35% to -$24.3 million in 2025.
  • Its Net Income was -$24.3 million in Q3 2025, compared to -$33.9 million in Q2 2025 and -$23.5 million in Q1 2025.